SRR25617823
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.420
- G2M_CHECKPOINT+0.310
- ALLOGRAFT_REJECTION+0.250
- SPERMATOGENESIS+0.210
- KRAS_SIGNALING_DN+0.190
- PANCREAS_BETA_CELLS+0.180
- MTORC1_SIGNALING+0.150
- IL6_JAK_STAT3_SIGNALING+0.100
- MYC_TARGETS_V1+0.100
- DNA_REPAIR+0.080
Top 10 suppressed
- TGF_BETA_SIGNALING-0.490
- UV_RESPONSE_DN-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ESTROGEN_RESPONSE_EARLY-0.450
- NOTCH_SIGNALING-0.410
- PROTEIN_SECRETION-0.360
- ANDROGEN_RESPONSE-0.350
- HYPOXIA-0.350
- TNFA_SIGNALING_VIA_NFKB-0.350
- ESTROGEN_RESPONSE_LATE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-AA6T-01A-11R-A39I-07 | — | — | 0.901 |
| 2 | SRR25617831 | — | D | 0.870 |
| 3 | TCGA-CR-5248-01A-01R-2016-07 | — | — | 0.852 |
| 4 | C3N-03080 | — | cohortSQ1 | 0.850 |
| 5 | SRR25617851 | — | B | 0.836 |
| 6 | SRR25617852 | — | B | 0.825 |
| 7 | 6d64d560-bb58-4868-bf12-d6833b626721 | — | — | 0.822 |
| 8 | SRR934790 | — | — | 0.821 |
| 9 | MDT-AP-1162 | Med | Medulloblastoma | 0.812 |
| 10 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |